{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:54:02Z","timestamp":1790754842369,"version":"4.1.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.phrs.2020.104806","type":"journal-article","created":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T17:58:04Z","timestamp":1586714284000},"page":"104806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer \u2013 A comprehensive review from chemotherapy to immunotherapy"],"prefix":"10.1016","volume":"156","author":[{"given":"Parham","family":"Jabbarzadeh Kaboli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Salimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil","family":"Aghapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueshui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Hin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104806_bib0005","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.7314\/APJCP.2013.14.6.3779","article-title":"Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study","volume":"14","author":"Li","year":"2013","journal-title":"Asian Pacific J. Cancer Prev."},{"key":"10.1016\/j.phrs.2020.104806_bib0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2020.104806_bib0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jama.2018.20751","article-title":"Breast Cancer treatment","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2020.104806_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/modpathol.2009.145","article-title":"Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer","volume":"23","author":"Thike","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.phrs.2020.104806_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0030","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/ijo.2015.3306","article-title":"Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review)","volume":"48","author":"Nitulescu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","article-title":"Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: new discoveries and practical insights for drug development","volume":"53","author":"Costa","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2020.104806_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081050","article-title":"PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast Cancer","volume":"11","author":"Saleh","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2020.104806_bib0045","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/1535-7163.MCT-17-0026","article-title":"TRA2A promoted paclitaxel resistance and tumor progression in triple-negative breast cancers via regulating alternative splicing","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0050","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1038\/ncomms9746","article-title":"IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel","volume":"6","author":"Wee","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.104806_bib0055","doi-asserted-by":"crossref","first-page":"E5429","DOI":"10.1073\/pnas.1421438111","article-title":"Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells","volume":"111","author":"Samanta","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2020.104806_bib0060","doi-asserted-by":"crossref","first-page":"99901","DOI":"10.18632\/oncotarget.21914","article-title":"PD-1\/PD-L1 interaction up-regulates MDR1\/P-gp expression in breast cancer cells via PI3K\/AKT and MAPK\/ERK pathways","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.104806_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharep.2018.07.005","article-title":"Antitumor effects of berberine against EGFR, ERK1\/2, P38 and AKT in MDA-MB231 and MCF-7 breast Cancer cells using molecular modelling and in vitro study","volume":"71","author":"Jabbarzadeh Kaboli","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0070","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/brain\/awx203","article-title":"Mutations of AKT3 are associated with a wide spectrum of developmental disorders including extreme megalencephaly","volume":"140","author":"Alcantara","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2020.104806_bib0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-008-0097-z","article-title":"Calmodulin modulates Akt activity in human breast cancer cell lines","volume":"115","author":"Coticchia","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0080","doi-asserted-by":"crossref","first-page":"27403","DOI":"10.1074\/jbc.M115.673939","article-title":"Structural and biophysical characterization of the interactions between Calmodulin and the pleckstrin homology domain of akt","volume":"290","author":"Agamasu","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0085","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsb1203-980","article-title":"Announcing the worldwide protein data bank","volume":"10","author":"Berman","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1042\/bj20031229","article-title":"Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change","volume":"375","author":"Milburn","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2020.104806_bib0095","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1016\/j.bmcl.2010.08.053","article-title":"Discovery of pyrrolopyrimidine inhibitors of Akt","volume":"20","author":"Blake","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.104806_bib0100","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1093\/bioinformatics\/bty419","article-title":"NGL viewer: web-based molecular graphics for large complexes","volume":"34","author":"Rose","year":"2018","journal-title":"Bioinformatics."},{"key":"10.1016\/j.phrs.2020.104806_bib0105","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acschembio.6b01014","article-title":"Lysine deacetylation by HDAC6 regulates the kinase activity of AKT in human neural progenitor cells","volume":"12","author":"Iaconelli","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0110","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1021\/bi500428j","article-title":"Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase","volume":"53","author":"Sierecki","year":"2014","journal-title":"Biochemistry."},{"key":"10.1016\/j.phrs.2020.104806_bib0115","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/cddis.2014.118","article-title":"Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt\/GSK3\u03b2\/Fyn kinase axis during oxidative hepatocellular toxicity","volume":"5","author":"Rizvi","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2020.104806_bib0120","article-title":"Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer \u2013 contradictory effects and future perspectives","volume":"121","author":"Kaboli","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2020.104806_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193941","article-title":"Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: a new group of RAF inhibitors for cancer treatment","volume":"13","author":"Jabbarzadeh Kaboli","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104806_bib0130","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0135","first-page":"E1024","article-title":"Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity, American Journal of Physiology","volume":"316","author":"Martins","year":"2019","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.104806_bib0140","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.7150\/jca.24275","article-title":"SIRT1 promotes formation of breast cancer through modulating Akt activity","volume":"9","author":"Jin","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0145","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/15384047.2015.1071731","article-title":"Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis","volume":"16","author":"Sarma","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0150","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1161\/CIRCRESAHA.113.300536","article-title":"Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging","volume":"114","author":"Pillai","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0155","doi-asserted-by":"crossref","first-page":"ra46","DOI":"10.1126\/scisignal.2001465","article-title":"The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy","volume":"4","author":"Sundaresan","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2020.104806_bib0160","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/s41467-019-13114-4","article-title":"Global redox proteome and phosphoproteome analysis reveals redox switch in Akt","volume":"10","author":"Su","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.104806_bib0165","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccell.2016.07.004","article-title":"Mitochondrial akt regulation of hypoxic tumor reprogramming","volume":"30","author":"Chae","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2020.104806_bib0170","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1126\/science.1175065","article-title":"The E3 ligase TRAF6 regulates Akt ubiquitination and activation","volume":"325","author":"Yang","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.phrs.2020.104806_bib0175","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41419-019-2142-8","article-title":"The many substrates and functions of NEDD4-1","volume":"10","author":"Huang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2020.104806_bib0180","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/cas.14012","article-title":"Tumor necrosis factor receptor-associated factor 6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation","volume":"110","author":"Shi","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phrs.2020.104806_bib0185","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cell.2012.02.065","article-title":"The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis","volume":"149","author":"Chan","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.phrs.2020.104806_bib0190","doi-asserted-by":"crossref","first-page":"ra3","DOI":"10.1126\/scisignal.2003197","article-title":"Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling","volume":"6","author":"Yang","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2020.104806_bib0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fonc.2012.00005","article-title":"K63-linked ubiquitination in kinase activation and cancer","volume":"2","author":"Wang","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0200","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1038\/s41467-018-07188-9","article-title":"The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance","volume":"9","author":"Han","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.104806_bib0205","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/onc.2009.315","article-title":"AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K","volume":"29","author":"Askham","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2020.104806_bib0210","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/cr.2012.38","article-title":"Akt is negatively regulated by the MULAN E3 ligase","volume":"22","author":"Bae","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0215","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1158\/0008-5472.CAN-08-3009","article-title":"Negative regulation of AKT activation by BRCA1","volume":"68","author":"Xiang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0220","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.devcel.2009.09.007","article-title":"The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt","volume":"17","author":"Suizu","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.phrs.2020.104806_bib0225","doi-asserted-by":"crossref","first-page":"14190","DOI":"10.1074\/jbc.M111.219923","article-title":"mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif","volume":"286","author":"Wu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0230","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.4161\/cc.26183","article-title":"Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle","volume":"12","author":"Risso","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2020.104806_bib0235","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41556-018-0266-1","article-title":"SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis","volume":"21","author":"Wang","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0092-8674(02)01083-8","article-title":"PKB binding proteins. Getting in on the Akt","volume":"111","author":"Brazil","year":"2002","journal-title":"Cell."},{"key":"10.1016\/j.phrs.2020.104806_bib0245","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2036-2","article-title":"Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer","volume":"134","author":"Li","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"Carew","year":"2011","journal-title":"Target. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0255","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/0008-5472.CAN-17-2388","article-title":"Selective mTORC2 inhibitor therapeutically blocks breast Cancer cell growth and survival","volume":"78","author":"Werfel","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0260","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1158\/0008-5472.CAN-15-3393","article-title":"Rictor\/mTORC2 drives progression and therapeutic resistance of HER2-Amplified breast cancers","volume":"76","author":"Morrison Joly","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0265","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.bbamcr.2013.05.005","article-title":"Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W","volume":"1833","author":"Jeon","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2020.104806_bib0270","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/bcr3611","article-title":"Runx2 activates PI3K\/Akt signaling via mTORC2 regulation in invasive breast cancer cells","volume":"16","author":"Tandon","year":"2014","journal-title":"Breast Cancer Research: BCR."},{"key":"10.1016\/j.phrs.2020.104806_bib0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.devcel.2016.04.011","article-title":"PRICKLE1 contributes to Cancer cell dissemination through its interaction with mTORC2","volume":"37","author":"Daulat","year":"2016","journal-title":"Dev. Cell"},{"key":"10.1016\/j.phrs.2020.104806_bib0280","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-07-2223","article-title":"mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor","volume":"67","author":"Masri","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0285","doi-asserted-by":"crossref","first-page":"e1005291","DOI":"10.1371\/journal.pgen.1005291","article-title":"mTOR directs breast morphogenesis through the PKC-alpha-Rac1 signaling Axis","volume":"11","author":"Morrison","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.phrs.2020.104806_bib0290","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ncb2507","article-title":"PRR5L degradation promotes mTORC2-mediated PKC-\u03b4 phosphorylation and cell migration downstream of G\u03b112","volume":"14","author":"Gan","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/onc.2012.30","article-title":"Role of the integrin-linked kinase (ILK)\/Rictor complex in TGF\u03b2-1-induced epithelial-mesenchymal transition (EMT)","volume":"32","author":"Serrano","year":"2013","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.104806_bib0300","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1158\/0008-5472.CAN-10-0207","article-title":"mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0305","first-page":"e229","article-title":"Protein phosphatase 2A: a target for anticancer therapy, the Lancet","volume":"14","author":"Perrotti","year":"2013","journal-title":"Oncology."},{"key":"10.1016\/j.phrs.2020.104806_bib0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1878-5085-5-3","article-title":"Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720","volume":"5","author":"Baldacchino","year":"2014","journal-title":"EPMA J."},{"key":"10.1016\/j.phrs.2020.104806_bib0315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104806_bib0320","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41419-018-0774-8","article-title":"Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT","volume":"9","author":"Zhao","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2020.104806_bib0325","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/jcm7090245","article-title":"SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment","volume":"7","author":"Huang","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2020.104806_bib0330","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.humpath.2017.06.001","article-title":"Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up","volume":"66","author":"Chen","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.phrs.2020.104806_bib0335","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1074\/jbc.275.13.9209","article-title":"Protein phosphatase 2A inhibitors, I(1)(PP2A) and I(2)(PP2A), associate with and modify the substrate specificity of protein phosphatase 1","volume":"275","author":"Katayose","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0340","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13058-014-0431-9","article-title":"Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells","volume":"16","author":"Liu","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0345","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr3175","article-title":"CIP2A is a target of bortezomib in human triple negative breast cancer cells","volume":"14","author":"Tseng","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0350","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3892\/or.2017.5667","article-title":"Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A","volume":"38","author":"Huang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0355","doi-asserted-by":"crossref","first-page":"58847","DOI":"10.18632\/oncotarget.19375","article-title":"Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.104806_bib0360","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.7150\/jca.35704","article-title":"Cip2a\/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer","volume":"10","author":"Yin","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0365","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2018.12.032","article-title":"Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression","volume":"40","author":"Liu","year":"2019","journal-title":"EBioMedicine."},{"key":"10.1016\/j.phrs.2020.104806_bib0370","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-4598-13-157","article-title":"PP2A inhibition overcomes acquired resistance to HER2 targeted therapy","volume":"13","author":"McDermott","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0375","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.18632\/oncotarget.3012","article-title":"PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects","volume":"6","author":"Rinc\u00f3n","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0380","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10495-014-1071-3","article-title":"FOXO3-mediated up-regulation of Bim contributes to rhein-induced cancer cell apoptosis","volume":"20","author":"Wang","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.phrs.2020.104806_bib0385","doi-asserted-by":"crossref","first-page":"42110","DOI":"10.18632\/oncotarget.9881","article-title":"Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0390","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1541-7786.MCR-18-0157","article-title":"CHP2 Promotes cell proliferation in breast Cancer via suppression of FOXO3a","volume":"16","author":"Zhao","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0395","doi-asserted-by":"crossref","first-page":"e83312","DOI":"10.1371\/journal.pone.0083312","article-title":"CHIP regulates AKT\/FoxO\/Bim signaling in MCF7 and MCF10A cells","volume":"8","author":"Lv","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104806_bib0400","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1038\/s41467-019-13700-6","article-title":"TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription","volume":"10","author":"Yu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.104806_bib0405","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12935-019-1050-4","article-title":"Uev1A promotes breast cancer cell survival and chemoresistance through the AKT-FOXO1-BIM pathway","volume":"19","author":"Wu","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.phrs.2020.104806_bib0410","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.gene.2016.10.016","article-title":"MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN\/Akt\/FOXO1 pathway","volume":"596","author":"Shen","year":"2017","journal-title":"Gene."},{"key":"10.1016\/j.phrs.2020.104806_bib0415","doi-asserted-by":"crossref","first-page":"43078","DOI":"10.1038\/srep43078","article-title":"Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis","volume":"7","author":"Procaccia","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0420","doi-asserted-by":"crossref","first-page":"27999","DOI":"10.1074\/jbc.M113.494328","article-title":"Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice","volume":"288","author":"Tinkum","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0425","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1038\/onc.2014.250","article-title":"CCN5\/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation","volume":"34","author":"Haque","year":"2015","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.104806_bib0430","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1093\/nar\/gkw027","article-title":"Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2","volume":"44","author":"Du","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0435","first-page":"371","article-title":"USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT\/Skp2 pathway","volume":"53","author":"Tan","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0440","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41598-017-00916-z","article-title":"Deficiency of CCN5\/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth","volume":"7","author":"Das","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0445","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12032-013-0735-0","article-title":"The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K\/Akt pathway and cell proliferation","volume":"30","author":"Liu","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0450","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1126\/scisignal.aao3810","article-title":"Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors","volume":"11","author":"Clement","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2020.104806_bib0455","doi-asserted-by":"crossref","DOI":"10.2174\/1570180817666200212125658","article-title":"Lapatinib as a dual tyrosine kinase inhibitor unexpectedly activates akt in MDA-MB-231 triple-negative breast Cancer cells","volume":"17","author":"Kaboli","year":"2020","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.phrs.2020.104806_bib0460","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10549-014-3014-7","article-title":"A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression","volume":"146","author":"Lee","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0465","doi-asserted-by":"crossref","first-page":"4629495","DOI":"10.1155\/2017\/4629495","article-title":"Multifaceted roles of GSK-3 in Cancer and autophagy-related diseases","volume":"2017","author":"Mancinelli","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2020.104806_bib0470","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.canlet.2016.07.006","article-title":"GSK-3 inhibition overcomes chemoresistance in human breast cancer","volume":"380","author":"Ugolkov","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.104806_bib0475","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1038\/onc.2014.390","article-title":"Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth","volume":"34","author":"Azoulay-Alfaguter","year":"2015","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.104806_bib0480","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3324\/haematol.2018.197749","article-title":"The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes","volume":"104","author":"Lin","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.phrs.2020.104806_bib0485","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopha.2018.02.112","article-title":"Suppression of Nrf2 confers chemosensitizing effect through enhanced oxidant-mediated mitochondrial dysfunction","volume":"101","author":"Sompakdee","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2020.104806_bib0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12551-016-0244-4","article-title":"The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases","volume":"9","author":"Deshmukh","year":"2017","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.phrs.2020.104806_bib0495","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biocel.2017.12.016","article-title":"NRF2 facilitates breast cancer cell growth via HIF1a-mediated metabolic reprogramming","volume":"95","author":"Zhang","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0500","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.redox.2019.101210","article-title":"Impairment of HIF-1\u03b1-mediated metabolic adaption by NRF2-silencing in breast cancer cells","volume":"24","author":"Lee","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0505","first-page":"1","article-title":"A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells","volume":"235","author":"De Blasio","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2020.104806_bib0510","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.25549","article-title":"Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways","volume":"55","author":"Chen","year":"2012","journal-title":"Hepatology."},{"key":"10.1016\/j.phrs.2020.104806_bib0515","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.yexcr.2014.08.030","article-title":"Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells","volume":"328","author":"Wu","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0520","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1073\/pnas.1324136111","article-title":"Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway","volume":"111","author":"Gorrini","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2020.104806_bib0525","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.freeradbiomed.2012.02.031","article-title":"NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity","volume":"52","author":"Manandhar","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2020.104806_bib0530","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ncb3341","article-title":"Glutathione biosynthesis is a metabolic vulnerability in PI(3)K\/Akt-driven breast cancer","volume":"18","author":"Lien","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0535","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/antiox8120633","article-title":"Chronic oxidative stress promotes molecular changes associated with epithelial mesenchymal transition, NRF2, and breast Cancer stem cell phenotype","volume":"8","author":"\u010cipak Ga\u0161parovi\u0107","year":"2019","journal-title":"Antioxidants."},{"key":"10.1016\/j.phrs.2020.104806_bib0540","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2018.00575","article-title":"Notch signaling regulates mitochondrial metabolism and NF-\u03baB activity in triple-negative breast Cancer cells via IKK\u03b1-Dependent non-canonical pathways","volume":"8","author":"Hossain","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0545","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2015.00099","article-title":"Environmental and metabolic sensors that control T cell biology","volume":"6","author":"Ramsay","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.104806_bib0550","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/s41467-018-06893-9","article-title":"Collagen prolyl 4-hydroxylase 1 is essential for HIF-1\u03b1 stabilization and TNBC chemoresistance","volume":"9","author":"Xiong","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.104806_bib0555","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s13402-011-0053-5","article-title":"Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1\u03b1 expression","volume":"34","author":"Hyseni","year":"2011","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0560","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cancergencyto.2005.05.008","article-title":"Mutation analysis of the HIF-1\u03b1 oxygen-dependent degradation domain in invasive breast cancer","volume":"163","author":"Vleugel","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.phrs.2020.104806_bib0565","doi-asserted-by":"crossref","first-page":"88955","DOI":"10.1371\/journal.pone.0088955","article-title":"Proline-hydroxylated hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) upregulation in human tumours","volume":"9","author":"Snell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104806_bib0570","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/HP.S60703","article-title":"Direct phosphorylation events involved in HIF-\u03b1 regulation: the role of GSK-3\u03b2","volume":"2","author":"Mennerich","year":"2014","journal-title":"Hypoxia"},{"key":"10.1016\/j.phrs.2020.104806_bib0575","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ncb3295","article-title":"The LINK-A lncRNA activates normoxic HIF1\u03b1 signalling in triple-negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0580","doi-asserted-by":"crossref","first-page":"27620","DOI":"10.1074\/jbc.M803081200","article-title":"Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1\u03b1 by MAPK","volume":"283","author":"Mylonis","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0585","doi-asserted-by":"crossref","first-page":"33095","DOI":"10.1074\/jbc.M605058200","article-title":"Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1\u03b1","volume":"281","author":"Mylonis","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0590","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/0008-5472.CAN-18-0270","article-title":"Reciprocal regulation of DUSP9 and DUSP16 expression by HIF1 controls ERK and p38 MAP kinase activity and mediates chemotherapy-induced breast Cancer stem cell enrichment","volume":"78","author":"Lu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0595","first-page":"830","article-title":"Triptolide inhibits vascular endothelial growth factor-mediated angiogenesis in human breast cancer cells","volume":"16","author":"Liu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phrs.2020.104806_bib0600","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13402-014-0182-8","article-title":"Translational suppression of HIF-1\u03b1 by miconazole through the mTOR signaling pathway","volume":"37","author":"Park","year":"2014","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0605","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/sj.onc.1209643","article-title":"Hypoxia-inducible factor-1\u03b1 expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas","volume":"25","author":"Gort","year":"2006","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.104806_bib0610","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1440-1681.12693","article-title":"Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1\u03b1 and HIF2\u03b1","volume":"44","author":"Sch\u00f6ning","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.phrs.2020.104806_bib0615","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbrc.2015.09.076","article-title":"The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1\u03b1 expression in breast cancer cells","volume":"467","author":"Shao","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2020.104806_bib0620","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.18632\/oncotarget.2806","article-title":"Hypoxia\/HIF1\u03b1 induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2","volume":"6","author":"Karakashev","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0625","doi-asserted-by":"crossref","first-page":"3907147","DOI":"10.1155\/2016\/3907147","article-title":"The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in Cancer initiation and progression","volume":"2016","author":"Tafani","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2020.104806_bib0630","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ceca.2019.03.002","article-title":"TRPM2 in Cancer","volume":"80","author":"Miller","year":"2019","journal-title":"Cell Calcium"},{"key":"10.1016\/j.phrs.2020.104806_bib0635","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1242\/jcs.196659","article-title":"TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells","volume":"130","author":"Azimi","year":"2017","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.phrs.2020.104806_bib0640","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-015-3266-x","article-title":"First trimester human placental factors induce breast cancer cell autophagy","volume":"149","author":"Epstein Shochet","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0645","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1111\/jcmm.13800","article-title":"Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K\/Akt pathway","volume":"22","author":"Pei","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2020.104806_bib0650","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biopha.2015.11.005","article-title":"Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells","volume":"77","author":"Yu","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2020.104806_bib0655","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1038\/s41598-019-44828-6","article-title":"ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0660","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ejphar.2014.06.025","article-title":"Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer","volume":"740","author":"Jabbarzadeh Kaboli","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104806_bib0665","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/ijms18030591","article-title":"GSK3\u03b2 and VDAC involvement in ER stress and apoptosis modulation during orthotopic liver transplantation","volume":"18","author":"Zaouali","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.104806_bib0670","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.18632\/oncotarget.2265","article-title":"Beclin-1-independent autophagy positively regulates internal ribosomal entry site-dependent translation of hypoxia-inducible factor 1\u03b1 under nutrient deprivation","volume":"5","author":"Wu","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0675","doi-asserted-by":"crossref","first-page":"25755","DOI":"10.18632\/oncotarget.4697","article-title":"Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K\/AKT and p53 signaling pathways","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0680","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","article-title":"Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics","volume":"15","author":"Navarro","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0685","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.104806_bib0690","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1471-4159.2009.05878.x","article-title":"The basal flux of Akt in the mitochondria is mediated by heat shock protein 90","volume":"108","author":"Barksdale","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2020.104806_bib0695","doi-asserted-by":"crossref","first-page":"9919","DOI":"10.1038\/s41598-019-46359-6","article-title":"Mitochondrial akt signaling modulated reprogramming of somatic cells","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0700","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1073\/pnas.1302455110","article-title":"mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology","volume":"110","author":"Betz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2020.104806_bib0705","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.freeradbiomed.2019.10.413","article-title":"Flavonoid GL-V9 induces apoptosis and inhibits glycolysis of breast cancer via disrupting GSK-3\u03b2-modulated mitochondrial binding of HKII","volume":"146","author":"Guo","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2020.104806_bib0710","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/embor.2009.249","article-title":"Apoptosis: it\u2019s BAK to VDAC","volume":"10","author":"Shore","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2020.104806_bib0715","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.yexcr.2018.12.002","article-title":"Zinc and p53 disrupt mitochondrial binding of HK2 by phosphorylating VDAC1","volume":"374","author":"Xue","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0720","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1242\/jcs.195339","article-title":"Mortalin-mediated and ERK-controlled targeting of HIF-1\u03b1 to mitochondria confers resistance to apoptosis under hypoxia","volume":"130","author":"Mylonis","year":"2017","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.phrs.2020.104806_bib0725","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.15252\/emmm.201910638","article-title":"Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer","volume":"11","author":"Ye","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2020.104806_bib0730","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10549-010-1304-2","article-title":"Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells","volume":"130","author":"Phuong","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0735","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.3390\/ma8105358","article-title":"The histone deacetylase inhibitor JAHA down-regulates pERK and global DNA methylation in MDA-MB231 breast Cancer cells","volume":"8","author":"Librizzi","year":"2015","journal-title":"Materials"},{"key":"10.1016\/j.phrs.2020.104806_bib0740","doi-asserted-by":"crossref","first-page":"018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0745","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-014-2877-y","article-title":"mTORC1\/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms","volume":"144","author":"Wilson-Edell","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0750","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.08.069","article-title":"Targeting breast cancer stem cells by novel HDAC3-selective inhibitors","volume":"140","author":"Hsieh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0755","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2011.03.019","article-title":"HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance","volume":"307","author":"Huang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.104806_bib0760","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2174\/1871520619666190312125602","article-title":"Recent development in indole derivatives as anticancer agents for breast Cancer","volume":"19","author":"Kaur","year":"2019","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0765","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-008-0148-5","article-title":"Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells","volume":"117","author":"Zhou","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2020.104806_bib0770","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/ijc.28182","article-title":"Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt\/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor","volume":"133","author":"Vilquin","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0775","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13058-014-0430-x","article-title":"Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase","volume":"16","author":"Fu","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0780","doi-asserted-by":"crossref","first-page":"497","DOI":"10.23736\/S0026-4784.18.04316-2","article-title":"Gonadotropin-releasing hormone analog therapeutics","volume":"70","author":"Newton","year":"2018","journal-title":"Minerva Ginecol."},{"key":"10.1016\/j.phrs.2020.104806_bib0785","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"Park","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0790","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3892\/ijo.2012.1591","article-title":"Inhibition of the AKT\/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells","volume":"41","author":"Block","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0795","article-title":"Molecular markers of regulatory t cells in Cancer immunotherapy with special focus on acute myeloid leukemia (AML) - a systematic review","author":"Kaboli","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104806_bib0800","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ijc.30834","article-title":"PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K\/AKT pathway activation","volume":"141","author":"Almozyan","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0805","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","article-title":"MiR-873\/PD-L1 axis regulates the stemness of breast cancer cells","volume":"41","author":"Gao","year":"2019","journal-title":"EBioMedicine."},{"key":"10.1016\/j.phrs.2020.104806_bib0810","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/1873-3468.12985","article-title":"E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer","volume":"592","author":"Wang","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2020.104806_bib0815","first-page":"865","article-title":"PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer, Cancer Immunology","volume":"66","author":"Okita","year":"2017","journal-title":"Immunotherapy."},{"key":"10.1016\/j.phrs.2020.104806_bib0820","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene."},{"key":"10.1016\/j.phrs.2020.104806_bib0825","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.trsl.2018.05.011","article-title":"Epigenetic regulators of programmed death-ligand 1 expression in human cancers","volume":"202","author":"Kumar","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0830","doi-asserted-by":"crossref","first-page":"1008824","DOI":"10.1080\/2162402X.2015.1008824","article-title":"Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression","volume":"4","author":"Bellucci","year":"2015","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.phrs.2020.104806_bib0835","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12885-018-4384-8","article-title":"CXCL9\/10\/11, a regulator of PD-L1 expression in gastric cancer","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0840","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12885-019-5364-3","article-title":"Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2020.104806_bib0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0850","first-page":"5399","article-title":"PD-L1 expression levels on tumor cells affect their immunosuppressive activity","volume":"18","author":"Zheng","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2020.104806_bib0855","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.3390\/molecules25020252","article-title":"Inhibitory effect of Hesperidin on the expression of programmed death ligand (PD-L1) in breast Cancer","volume":"25","author":"Kongtawelert","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.phrs.2020.104806_bib0860","doi-asserted-by":"crossref","first-page":"110392","DOI":"10.18632\/oncotarget.22778","article-title":"Inhibition of PI4K III\u03b1 radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0865","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3892\/ijo.2015.3062","article-title":"Combining AZD8931, a novel EGFR\/HER2\/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models","volume":"47","author":"Crafter","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0870","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-15-0230","article-title":"Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors","volume":"14","author":"Davies","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0875","doi-asserted-by":"crossref","DOI":"10.1177\/0734242X19893006","article-title":"A unit-cell model for thermal regulation of degradation of organics in solid waste","author":"Shi","year":"2020","journal-title":"Waste Manag. Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0880","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1158\/1535-7163.MCT-15-0748","article-title":"Upregulation of AKT3 confers resistance to the AKT inhibitor MK2206 in breast Cancer","volume":"15","author":"Stottrup","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0885","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.2147\/OTT.S207723","article-title":"TRIM11 promotes proliferation and glycolysis of breast cancer cells via targeting AKT\/GLUT1 pathway","volume":"12","author":"Song","year":"2019","journal-title":"Onco. Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0890","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bbadis.2018.01.031","article-title":"STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells, Biochimica et Biophysica Acta","volume":"1864","author":"Nan","year":"2018","journal-title":"Molecular Basis of Disease."},{"key":"10.1016\/j.phrs.2020.104806_bib0895","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","article-title":"Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation","volume":"21","author":"Xing","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0900","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"O\u2019Donnell","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2020.104806_bib0905","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1535-7163.MCT-15-0143","article-title":"AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast Cancer and synergizes with fulvestrant (ICI182780) in vivo","volume":"14","author":"Ribas","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0910","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdz086","article-title":"BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA","volume":"30","author":"Turner","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2020.104806_bib0915","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-19-3053","article-title":"Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast Cancer (STAKT)","volume":"26","author":"Robertson","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0920","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/cancers11091359","article-title":"Allosteric AKT inhibitors target synthetic lethal vulnerabilities in E-Cadherin-Deficient cells","volume":"11","author":"Bougen-Zhukov","year":"2019","journal-title":"Cancers."},{"key":"10.1016\/j.phrs.2020.104806_bib0925","doi-asserted-by":"crossref","first-page":"0133219","DOI":"10.1371\/journal.pone.0133219","article-title":"Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast Cancer","volume":"10","author":"Korkola","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104806_bib0930","first-page":"806","article-title":"M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier","volume":"6","author":"Machl","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0935","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2018.09.062","article-title":"Preparation of lapatinib ditosylate solid dispersions using solvent rotary evaporation and hot melt extrusion for solubility and dissolution enhancement","volume":"552","author":"Hu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2020.104806_bib0940","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1535-7163.MCT-19-0261","article-title":"Transgelin 2 promotes paclitaxel resistance, migration, and invasion of breast Cancer by directly interacting with PTEN and activating PI3K\/Akt\/GSK-3\u03b2 pathway","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104806_bib0945","doi-asserted-by":"crossref","first-page":"73947","DOI":"10.18632\/oncotarget.18166","article-title":"Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth","volume":"8","author":"Carpenter","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.phrs.2020.104806_bib0950","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1158\/1078-0432.CCR-17-1260","article-title":"A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative breast Cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0955","doi-asserted-by":"crossref","first-page":"0175779","DOI":"10.1371\/journal.pone.0175779","article-title":"Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients","volume":"12","author":"de Bruin","year":"2017","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.phrs.2020.104806_bib0960","first-page":"30817","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"1470-2045","author":"Jones","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2018","key":"10.1016\/j.phrs.2020.104806_bib0965","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12254-018-0450-9","article-title":"Highlights: metastatic breast cancer","volume":"11","author":"Rinnerthaler","year":"2018","journal-title":"Memo."},{"key":"10.1016\/j.phrs.2020.104806_bib0970","doi-asserted-by":"crossref","first-page":"21444","DOI":"10.18632\/oncotarget.25118","article-title":"Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer","volume":"9","author":"Avivar-Valderas","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.104806_bib0975","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.21873\/anticanres.11170","article-title":"Co-treatment of LY294002 or MK-2206 with AZD5363 attenuates AZD5363-induced increase in the level of phosphorylated AKT","volume":"36","author":"Choi","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0980","first-page":"4741","article-title":"Co-treatment of salinomycin sensitizes AZD5363-treated Cancer cells through increased apoptosis","volume":"35","author":"Choi","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2020.104806_bib0985","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","article-title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors","volume":"85","author":"Tolcher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:11:24Z","timestamp":1760911884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820311142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":197,"alternative-id":["S1043661820311142"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104806","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer \u2013 A comprehensive review from chemotherapy to immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104806"}}